Skip to main content
. 2016 Feb 2;7(9):9876–9889. doi: 10.18632/oncotarget.7130

Figure 6.

Figure 6

(A) Upper left blot shows IP of phosphorylated RTK-AXL in 8 patients with primary glioblastoma multiforme (pGBM), lower blot shows phosphorylated RTK-AXL in 8 patients with recurrent glioblastoma multiforme (rGBM). Upper right blot shows following control samples: positive ctrl: SF126 tumor mice, patient #37: meningeoma WHO°I, patient #20: arachnoidal cyst, negative ctrl: beads incubated with antibody and sample diluent. (B) Staining of phosphorylated RTK-AXL in human glioblastoma multiforme tissue (huGBM). Upper left image shows membrane bound staining of tumor cells (arrow). Scale bar of upper left image indicates 10 μm. Lower left image shows staining of phosphorylated RTK-AXL of tumor vessels (arrow). RTK-AXL phosphorylation is also observed in tumor pseudo-palisades (arrow) adjacent to necrotic areas (star, upper right image). Lower right images shows negative control staining of healthy brain tissue. Scale bar indicates 50 μm.